20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

About this update from 20/20 Biolabs, Inc.

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today highlighted key themes from its inaugural investor webinar held on July 1, 2026. The Company presented its strategy for advancing OneTest™ for Cancer toward potential Medicare reimbursement under the new statutory pathway for FDA-authorized multi-cancer early detection ("MCED") blood tests beginning in 2028. The Company highlighted recent federal legislation creating a Medicare coverage pathway for MCED tests, together with evolving clinical evidence and real-world screening data, which may create a significant long-term opportunity for affordable, accessible MCED testing. The Company emphasized that Medicare reimbursement for OneTest™ would require FDA authorization and a CMS determination of clinical appropriateness, neither of which has been obtained, and there can be no assurance that such authorization, coverage, or reimbursement will be achieved whatsoever. During the presentation, the Company demonstrated how OneTest™ differs from circulating tumor DNA-based MCED approaches by using a panel of protein tumor markers, inflammation-associated biomarkers, machine learning, and serial testing to monitor biomarker trajectories over time rather than relying on a single snapshot. The Company believes this approach may support earlier detection, improved specificity through trend analysis, and more practical repeat testing using at-home capillary blood collection. The Company also detailed its evidence-generation strategy, including the use of real-world screening data, international clinical datasets, published "look-alike" protein tumor marker panel studies, potential validation using banked U.S. biospecimens, and outcomes from high-risk populations such as firefighters. The Company noted that more than 35,000 American firefighters are expected to have been tested by the end of 2026. The Company expects this population to provide important real-world data to support its regulatory and reimbursement strategy. The Company also indicated that its second quarter MCED revenue is expected to be its highest to date, and at least 30% higher than the prior-year second quarter (three months ended June 30, 2025). These estimates are based on preliminary numbers that have not yet been reviewed by our auditors.

View stock analysis, news, and events for 20/20 Biolabs, Inc.